Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
STOXIL is an ophthalmic ointment small molecule approved in 1967 by GSK for treatment of viral eye infections. The exact mechanism of action and specific indications are not publicly detailed in available data, but the product represents a legacy antiviral therapy in ophthalmology. As a 1967 NDA approval, it is among the oldest marketed pharmaceuticals still in distribution.
Product approaching loss of exclusivity with low commercial activity, indicating a contraction-phase team focused on generic transition planning rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
No current job postings are linked to STOXIL, reflecting its legacy status and minimal commercial footprint. Roles on this product are typically focused on managing generic transition, regulatory compliance, and wind-down planning rather than growth or innovation.
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.